The Effect of AI-based Microbiome Diet on IBS-M Symptoms

Irritable Bowel Syndrome Mixed Clinical Trial

Official title: An Open-labelled Interventional Study With 25 IBS-M Patients in Which Group 1 (n=14) Followed Six Weeks of AI-based Microbiome Diet and Group 2 (n=11) Followed Standard IBS Diet

Status Completed

Clinical Trial Summary

This study was designed as a pilot, open-labelled study. We enrolled consecutive IBS-M patients (n=25, 19 females, 46.06 ± 13.11 years) according to Rome IV criteria. Fecal samples were obtained from all patients twice (pre- and post-intervention) and high-throughput 16S rRNA sequencing was performed. Patients were divided into two groups based on age, gender and microbiome matched. Six weeks of AI-based microbiome diet (n=14) for group 1 and standard IBS diet (Control group, n=11) for group 2 were followed. AI-based diet was designed based on optimizing a personalized nutritional strategy by an algorithm regarding individual gut microbiome features. An algorithm assessing an IBS index score using microbiome composition attempted to design the optimized diets based on modulating microbiome towards the healthy scores. Baseline and post-intervention IBS-SSS (symptom severity scale) scores and fecal microbiome analyses were compared.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Irritable Bowel Syndrome
• Irritable Bowel Syndrome Mixed

• NCT number: NCT04768387
• Study type: Interventional
• Source: Gazi University
• Status: Completed
• Phase: N/A
• Start date: October 5, 2020
• Completion date: January 15, 2021